{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:37:21Z","timestamp":1791301041599,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,3,18]],"date-time":"2015-03-18T00:00:00Z","timestamp":1426636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,3,18]],"date-time":"2015-03-18T00:00:00Z","timestamp":1426636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1038\/leu.2015.73","type":"journal-article","created":{"date-parts":[[2015,3,18]],"date-time":"2015-03-18T07:33:13Z","timestamp":1426663993000},"page":"1336-1343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":217,"title":["The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries"],"prefix":"10.1038","volume":"29","author":[{"given":"V S","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hasford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Lindoerfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Burgstaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Sertic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Costeas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Indrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Everaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Koskenvesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Schubert-Fritschle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Lejniece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Griskevicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Thielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Sacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A G","family":"Turkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Zaritskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Bogdanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Sninska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Zupan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-L","family":"Steegmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Simonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R E","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Covelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Guidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,18]]},"reference":[{"key":"BFleu201573_CR1","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M, on behalf of the European LeukemiaNet. Chronic myeloid leukaemia. Lancet 2007; 370: 342\u201350.","journal-title":"Lancet"},{"key":"BFleu201573_CR2","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bj\u00f6rkholm","year":"2011","unstructured":"Bj\u00f6rkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sj\u00f6berg J et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011; 29: 2514\u20132520.","journal-title":"J Clin Oncol"},{"key":"BFleu201573_CR3","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","volume":"119","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, O\u2019Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012; 119: 1981\u20131987.","journal-title":"Blood"},{"key":"BFleu201573_CR4","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872\u2013884.","journal-title":"Blood"},{"key":"BFleu201573_CR5","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.6004\/jnccn.2013.0157","volume":"11","author":"S O\u2019Brien","year":"2013","unstructured":"O\u2019Brien S, Abboud CN, Akhtari M, Altman J, Berman E, DeAngelo DJ et al. Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Netw 2013; 11: 1327\u20131340.","journal-title":"J Natl Compr Canc Netw"},{"key":"BFleu201573_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrd2873","volume":"8","author":"S Storey","year":"2009","unstructured":"Storey S . Chronic myelogenous leukaemia market. Nat Rev Drug Discov 2009; 8: 447\u2013448.","journal-title":"Nat Rev Drug Discov"},{"key":"BFleu201573_CR7","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H . Estimation of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 2012; 118: 3123\u20133127.","journal-title":"Cancer"},{"key":"BFleu201573_CR8","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","volume":"121","author":"Experts in Chronic Myeloid Leukemia (Kantarjian H. et al.)","year":"2013","unstructured":"Experts in Chronic Myeloid Leukemia (Kantarjian H. et al.). The price of drugs for chronic myeloid leukemia (CML) is a reflection on the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013; 121: 4439\u20134442.","journal-title":"Blood"},{"key":"BFleu201573_CR9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994\u20131004.","journal-title":"N Engl J Med"},{"key":"BFleu201573_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW et al. Phase III, randomized, open-label study of daily imatinib mesylate 400\u2009mg versus 800\u2009mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010; 28: 424\u2013430.","journal-title":"J Clin Oncol"},{"key":"BFleu201573_CR11","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu201573_CR12","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260\u20132270.","journal-title":"N Engl J Med"},{"key":"BFleu201573_CR13","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Br\u00fcmmendorf TH, Dyagil I, Griskevicius L et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012; 30: 3486\u20133492.","journal-title":"J Clin Oncol"},{"key":"BFleu201573_CR14","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1200\/JCO.2009.26.7963","volume":"28","author":"F Castagnetti","year":"2010","unstructured":"Castagnetti F, Testoni N, Luatti S, Marzocchi G, Mancini M, Kerim S et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. J Clin Oncol 2010; 28: 2748\u20132754.","journal-title":"J Clin Oncol"},{"key":"BFleu201573_CR15","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","volume":"117","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML working party. Blood 2011; 117: 5591\u20135599.","journal-title":"Blood"},{"key":"BFleu201573_CR16","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363: 2511\u20132521.","journal-title":"N Engl J Med"},{"key":"BFleu201573_CR17","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, M\u00fcller MC, Pletsch N et al. Tolerability-adapted imatinib 800\u2009mg\/d versus 400\u2009mg\/d versus 400\u2009mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29: 1634\u20131642.","journal-title":"J Clin Oncol"},{"key":"BFleu201573_CR18","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H de Lavallade","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad J, Milojkovic D, Reid AG, Bua M et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358\u20133363.","journal-title":"J Clin Oncol"},{"key":"BFleu201573_CR19","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","volume":"121","author":"P Jain","year":"2013","unstructured":"Jain P, Kantarjian H, Nazha A, O\u2019Brien S, Jabbour E, Romo CG et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 2013; 121: 4867\u20134874.","journal-title":"Blood"},{"key":"BFleu201573_CR20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686\u2013692.","journal-title":"Blood"},{"key":"BFleu201573_CR21","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/leu.2013.171","volume":"27","author":"VS Hoffmann","year":"2013","unstructured":"Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 2013; 27: 2016\u20132022.","journal-title":"Leukemia"},{"key":"BFleu201573_CR22","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M H\u00f6glund","year":"2013","unstructured":"H\u00f6glund M, Sandin F, Hellstr\u00f6m K, Bj\u00f6reman M, Bj\u00f6rkholm M, Brune M et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 2013; 122: 1284\u20131292.","journal-title":"Blood"},{"key":"BFleu201573_CR23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in \u2018good-risk\u2019 chronic granulocytic leukemia. Blood 1984; 63: 789\u2013799.","journal-title":"Blood"},{"key":"BFleu201573_CR24","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998; 90: 850\u2013858.","journal-title":"J Natl Cancer Inst."},{"key":"BFleu201573_CR25","unstructured":"Waterhouse JAH, Muir CS, Correa P, Powell J (eds). Cancer incidence in five continents. IARC: Lyon, France, 1976; 3: 456."},{"key":"BFleu201573_CR26","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"A Fabarius","year":"2011","unstructured":"Fabarius A, Leitner A, Hochhaus A, M\u00fcller MC, Hanfstein B, Haferlach C et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118: 6760\u20136768.","journal-title":"Blood"},{"key":"BFleu201573_CR27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","volume":"120","author":"S Luatti","year":"2012","unstructured":"Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 2012; 120: 761\u2013767.","journal-title":"Blood"},{"key":"BFleu201573_CR28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C et al. Multicenter independent assessment of oucomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011; 103: 553\u2013561.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu201573_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/(SICI)1099-1069(199711)15:4<173::AID-HON610>3.0.CO;2-K","volume":"15","author":"RJ McNally","year":"1997","unstructured":"McNally RJ, Rowland D, Roman E, Cartwright RA . Age and sex distribution of haematological malignancies in the UK. Hematol Oncol 1997; 15: 173\u2013189.","journal-title":"Hematol Oncol"},{"key":"BFleu201573_CR30","first-page":"1400","volume":"91","author":"KJ Phekoo","year":"2006","unstructured":"Phekoo KJ, Richards MA, Moller H, Schey SA . The incidence and outcome of myeloid malignancies in 2112 adult patients in south-east England. Haematologica 2006; 91: 1400\u20131404.","journal-title":"Haematologica"},{"key":"BFleu201573_CR31","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/leu.2008.245","volume":"23","author":"M Rohrbacher","year":"2009","unstructured":"Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph\/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2009; 23: 602\u2013604.","journal-title":"Leukemia"},{"key":"BFleu201573_CR32","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116: 3724\u20133734.","journal-title":"Blood"},{"key":"BFleu201573_CR33","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","volume":"47","author":"G Gatta","year":"2011","unstructured":"Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I et al. Rare cancers are not so rare. Eur J Cancer 2011; 47: 2493\u20132511.","journal-title":"Eur J Cancer"},{"key":"BFleu201573_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3324\/haematol.2010.026252","volume":"96","author":"M Maynadi\u00e9","year":"2011","unstructured":"Maynadi\u00e9 M, Girodon F, Manivet-Janoray I, Mounier M, Mugneret F, Bailly F et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d\u2019Or (Burgundy, France). Haematologica 2011; 96: 55\u201361.","journal-title":"Haematologica"},{"key":"BFleu201573_CR35","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.3324\/haematol.2013.084061","volume":"98","author":"G Osca-Gelis","year":"2013","unstructured":"Osca-Gelis G, Puig-Vives M, Saez M, Gallardo D, Lloveras N, Marcos-Gragera R . Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain. Haematologica 2013; 98: e95\u2013e97.","journal-title":"Haematologica"},{"key":"BFleu201573_CR36","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data, November 2013 Sub (2000\u20132011) &lt;Katrina\/Rita Population Adjustment&gt;, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014, based on the November 2013 submission."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201573.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201573","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201573.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:16:09Z","timestamp":1648743369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,18]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["BFleu201573"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.73","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,18]]},"assertion":[{"value":"20 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"VSH, MB, JH and DL receive research funding from Novartis. NT and ZS have a consulting or advisory role at Novartis. AC and GG are employed by Novartis. KI has a consulting or advisory role at Amgen and Novartis. BS has a consulting or advisory role at BMS. AB receives funding of travel, accommodations or expenses from Novartis Oncology, Serbia. RH receives honoraria from BMS and research funding from Novartis and BMS. SB receives honoraria from Novartis, Celgene and AOP, has a consulting or advisory role at Novartis and Celgene, and receives funding of travel, accommodations or expenses from Novartis and AOP. AGT and JM have a consulting or advisory role at Novartis and BMS, and JM receives research funding and funding of travel, accommodations or expenses from Novartis and BMS. AZ has a consulting or advisory role at and participated in a speakers\u2019 bureau for Novartis and received research funding from BMS. LG receives research funding from Novartis and Roche and funding of travel, accommodations, or expenses from Novartis, Roche and Takeda. PK has a consulting or advisory role at GSK, BMS and Novartis, receives funding from Novartis, provides expert testimony for Pfizer and Novartis, and receives funding of travel, accommodations or expenses from BMS and Ariad. FR receives honoraria from BMS and Novartis, has a consulting or advisory role at BMS and Ariad, participated in a speakers\u2019 bureau for BMS and Novartis, and receives research funding from BMS. AH participated in a speakers\u2019 bureau for Novartis and BMS, receives research funding and funding of travel, accommodations or expenses from Novartis and BMS, and provides expert testimony for Novartis and BMS. FC has a consulting or advisory role and receives honoraria and funding of travel, accommodations or expenses from Novartis and BMS. TS has a consulting or advisory role at, participated in a speakers\u2019 bureau for and receives honoraria from Novartis, BMS, ADAMED and receives research funding and funding of travel, accommodations or expenses from Novartis and BMS. JLS has a consulting or advisory role at and receives honoraria and research funding from BMS, Novartis and Pfizer, and funding of travel, accommodations or expenses from BMS and Novartis. REC participated in a speakers\u2019 bureau for Novartis, receives funding from and has a consulting or advisory role at Novartis, BMS, Pfizer and Sanofi, and receives honoraria from Novartis, BMS, Pfizer, Sanofi and TEVA. The remaining authors declare no conflict of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}